| Style | Citing Format |
|---|---|
| MLA | Bagheri M, et al.. "Overexpression of Long Non‑Coding Rnas Mcm3ap‑As1 and Linc00092 Predict Poor Prognosis in Patients With Gastric Adenocarcinoma." Advanced Biomedical Research, vol. 13, no. 1, 2024, pp. -. |
| APA | Bagheri M, Aghaabdollahian S, Asghardoust Rezaei M, Gholian Kholerdi AM, Mehdi M, Keyvanloo Shahrestanaki M (2024). Overexpression of Long Non‑Coding Rnas Mcm3ap‑As1 and Linc00092 Predict Poor Prognosis in Patients With Gastric Adenocarcinoma. Advanced Biomedical Research, 13(1), -. |
| Chicago | Bagheri M, Aghaabdollahian S, Asghardoust Rezaei M, Gholian Kholerdi AM, Mehdi M, Keyvanloo Shahrestanaki M. "Overexpression of Long Non‑Coding Rnas Mcm3ap‑As1 and Linc00092 Predict Poor Prognosis in Patients With Gastric Adenocarcinoma." Advanced Biomedical Research 13, no. 1 (2024): -. |
| Harvard | Bagheri M et al. (2024) 'Overexpression of Long Non‑Coding Rnas Mcm3ap‑As1 and Linc00092 Predict Poor Prognosis in Patients With Gastric Adenocarcinoma', Advanced Biomedical Research, 13(1), pp. -. |
| Vancouver | Bagheri M, Aghaabdollahian S, Asghardoust Rezaei M, Gholian Kholerdi AM, Mehdi M, Keyvanloo Shahrestanaki M. Overexpression of Long Non‑Coding Rnas Mcm3ap‑As1 and Linc00092 Predict Poor Prognosis in Patients With Gastric Adenocarcinoma. Advanced Biomedical Research. 2024;13(1):-. |
| BibTex | @article{ author = {Bagheri M and Aghaabdollahian S and Asghardoust Rezaei M and Gholian Kholerdi AM and Mehdi M and Keyvanloo Shahrestanaki M}, title = {Overexpression of Long Non‑Coding Rnas Mcm3ap‑As1 and Linc00092 Predict Poor Prognosis in Patients With Gastric Adenocarcinoma}, journal = {Advanced Biomedical Research}, volume = {13}, number = {1}, pages = {-}, year = {2024} } |
| RIS | TY - JOUR AU - Bagheri M AU - Aghaabdollahian S AU - Asghardoust Rezaei M AU - Gholian Kholerdi AM AU - Mehdi M AU - Keyvanloo Shahrestanaki M TI - Overexpression of Long Non‑Coding Rnas Mcm3ap‑As1 and Linc00092 Predict Poor Prognosis in Patients With Gastric Adenocarcinoma JO - Advanced Biomedical Research VL - 13 IS - 1 SP - EP - PY - 2024 ER - |